Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is ...

Nektar said it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and reagent ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...

Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...